Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 17;19(9):2795.
doi: 10.3390/ijms19092795.

Immunogenic Effect of Hyperthermia on Enhancing Radiotherapeutic Efficacy

Sungmin Lee  1 , Beomseok Son  2 , Gaeul Park  3 , Hyunwoo Kim  4 , Hyunkoo Kang  5 , Jaewan Jeon  6 , HyeSook Youn  7 , BuHyun Youn  8   9
Affiliations
Review

Immunogenic Effect of Hyperthermia on Enhancing Radiotherapeutic Efficacy

Sungmin Lee et al. Int J Mol Sci. .

Abstract

Hyperthermia is a cancer treatment where tumor tissue is heated to around 40 °C. Hyperthermia shows both cancer cell cytotoxicity and immune response stimulation via immune cell activation. Immunogenic responses encompass the innate and adaptive immune systems, involving the activation of macrophages, natural killer cells, dendritic cells, and T cells. Moreover, hyperthermia is commonly used in combination with different treatment modalities, such as radiotherapy and chemotherapy, for better clinical outcomes. In this review, we will focus on hyperthermia-induced immunogenic effects and molecular events to improve radiotherapy efficacy. The beneficial potential of integrating radiotherapy with hyperthermia is also discussed.

Keywords: combination therapy; hyperthermia; immunotherapy; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declared that there is no interest to disclose.

Figures

Figure 1
Figure 1
Hyperthermia-induced immunogenicity in immune cells. Diagram summarizes the effects of hyperthermia and heat shock proteins (Hsps) in immune response enhancement in macrophage, dendritic cell, natural killer cell, endothelial cell, adaptive immune cells, and tumor cell. VEGF: vascular endothelial growth factor; iNOS: inducible nitric oxide (NO) synthase; CXCLs: chemokine (C-C motif) ligands; ICAM-1: intracellular adhesion molecule 1; VCAM-1: vascular cell adhesion molecule 1; TNF-α: tumor necrosis factor α; NKG2D: natural killer lectin-like receptor gene 2D. HSP: heat shock proteins; TLR: toll-like receptor; ILs: interleukins. The arrows indicate the upregulation effect by hyperthermia.
See this image and copyright information in PMC

References

    1. Santivasi W.L., Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid. Redox Signal. 2014;21:251–259. doi: 10.1089/ars.2013.5668. - DOI - PubMed
    1. Lim K., Small W., Jr., Portelance L., Creutzberg C., Jurgenliemk-Schulz I.M., Mundt A., Mell L.K., Mayr N., Viswanathan A., Jhingran A., et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011;79:348–355. doi: 10.1016/j.ijrobp.2009.10.075. - DOI - PubMed
    1. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760. doi: 10.1038/nature05236. - DOI - PubMed
    1. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–783. doi: 10.1038/nature07733. - DOI - PMC - PubMed
    1. de Boer S.M., Powell M.E., Mileshkin L., Katsaros D., Bessette P., Haie-Meder C., Ottevanger P.B., Ledermann J.A., Khaw P., Colombo A., et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): An open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:1114–1126. doi: 10.1016/S1470-2045(16)30120-6. - DOI - PubMed

LinkOut - more resources